Payment overview · 2025
General Payments
$86.13
6 reported records · 4 companies
Healthcare provider profile · identity verified
George Ellis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BOARDMAN, OH · NPI 1366428484
Verified facts
What the public records show
CMS Open Payments records show George Ellis, M.D. received $86.13 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 51.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.70 | 51.9% | 3 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $14.07 | 16.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.82 | 16.1% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $13.54 | 15.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $86.13 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.70 | 3 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 939 | 188 |
| Atorvastatin Calcium | Atorvastatin Calcium | 699 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 614 | 168 |
| Metoprolol Succinate | Metoprolol Succinate | 566 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 565 | 137 |
| Metformin Hcl Er | Metformin Hcl | 453 | 109 |
| Omeprazole | Omeprazole | 364 | 76 |
| Lisinopril | Lisinopril | 352 | 92 |
| Metformin Hcl | Metformin Hcl | 308 | 66 |
| Simvastatin | Simvastatin | 290 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 51 |
| Famotidine | Famotidine | 204 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 193 | 46 |
| Eliquis | Apixaban | 164 | 48 |
| Losartan Potassium | Losartan Potassium | 145 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 139 | 42 |
| Levetiracetam | Levetiracetam | 131 | 13 |
| Atenolol | Atenolol | 127 | 36 |
| Furosemide | Furosemide | 120 | 29 |
| Gabapentin | Gabapentin | 115 | 25 |
| Allopurinol | Allopurinol | 111 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 28 |
| Synthroid | Levothyroxine Sodium | 100 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 90 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 22 |
| Enulose | Lactulose | 87 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 30 |
| Alendronate Sodium | Alendronate Sodium | 78 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 14 |
| Ozempic | Semaglutide | 76 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 70 | suppressed |
| Januvia | Sitagliptin Phosphate | 70 | 16 |
| Potassium Chloride | Potassium Chloride | 70 | 21 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 69 | 11 |
| Carvedilol | Carvedilol | 68 | 11 |
| Warfarin Sodium | Warfarin Sodium | 65 | 12 |
| Divalproex Sodium | Divalproex Sodium | 64 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 64 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 12 |
| Labetalol Hcl | Labetalol Hcl | 61 | 13 |
| Prednisone | Prednisone | 59 | 24 |
| Oxcarbazepine | Oxcarbazepine | 58 | suppressed |
| Topiramate | Topiramate | 56 | suppressed |
| Ezetimibe | Ezetimibe | 55 | 12 |
| Sertraline Hcl | Sertraline Hcl | 55 | 20 |
| Baclofen | Baclofen | 53 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 52 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 52 | 12 |
| Bumetanide | Bumetanide | 49 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 47 | 13 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | suppressed |
| Carbamazepine | Carbamazepine | 44 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 13 |
| Spironolactone | Spironolactone | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Valsartan | Valsartan | 39 | 12 |
| Dutasteride | Dutasteride | 38 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Carbamazepine Er | Carbamazepine | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 11 |
| Lacosamide | Lacosamide | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | 16 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Cefdinir | Cefdinir | 34 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 26 |
| Methylprednisolone | Methylprednisolone | 34 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Phenobarbital | Phenobarbital | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Nadolol | Nadolol | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Acetazolamide | Acetazolamide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $86.13 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FREESTYLE LIBRE 3, GIMOTI, NP Thyroid 60 | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error